Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.

AIDS (London, England) - 23 Oct 2009

Ferns Ruth Bridget, Kirk Stuart, Bennett Julie, Cook Pamela M, Williams Ian, Edwards Simon, Pillay Deenan

Abstract excerpt

OBJECTIVES: To monitor HIV-1 integrase resistance mutations during raltegravir (RAL) therapy, including the impact of RAL interruption. DESIGN AND METHOD: An analysis of viral load and the HIV-1 integrase gene evolution in 26 HIV-1 treatment-experienced patients undergoing RAL therapy. RESULTS: Initial suppression of viral load was observed in all patients; however, four patients failed to maintain suppression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to HIV Infections

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Integrase

Share to Pyrrolidinones

Share to Raltegravir Potassium

Share to Sequence Analysis, RNA

Share to Treatment Failure

Share to Viral Load

Source

Identifiers

PMID: 19571721
DOI: 10.1097/QAD.0b013e32832ec4ae

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.PMID 19571721Read ↗

Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.Semantic proximity Read ↗

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.Semantic proximity Read ↗

Stable HIV-1 integrase diversity during initial HIV-1 RNA decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy.Semantic proximity Read ↗

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.Semantic proximity Read ↗

Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.Semantic proximity Read ↗

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral TherapySemantic proximity Read ↗

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.Semantic proximity Read ↗

Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.Semantic proximity Read ↗

HIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy.Semantic proximity Read ↗

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.Semantic proximity Read ↗

Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.Semantic proximity Read ↗

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.